B Group, Inc. reported CELLECTIS S A (CLLS) in 5 quarterly 13F filings from 2024 Q4 through 2025 Q4. Peak portfolio weight reached 11.73% in 2025 Q4. The latest visible filing shows CLLS at 11.73% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was B Group, Inc.'s position in CELLECTIS S A, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
CLLS was reported at 11.73% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
B Group, Inc. reported CLLS across 5 quarterly 13F filings, from 2024 Q4 through 2025 Q4.
The largest reported portfolio weight for CLLS was 11.73% in 2025 Q4.
The most recent filing on this page is 2025 Q4, when B Group, Inc. reported 3,281,501 shares, equal to 11.73% of portfolio, with an estimated market value of $15.9M.
The chart compares B Group, Inc.'s quarterly CLLS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent CLLS price moves, B Group, Inc. correctly timed 1 out of 3 reported position changes (33%). The annualised alpha on CLLS relative to SPY over the holding period was +112.8%.